Press Release

Kubota Vision Announces the Initiation of a Specific Clinical Trial Using eyeMO at Shinshu University Hospital

Seattle (October 23, 2024) — Kubota Vision Inc. ("Kubota Vision" or the "Company"), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that a specific clinical trial at Shinshu University Hospital (see May 7, 2024 press release titled "Kubota Vision Announces CRB Approval for a Specific Clinical Trial Using eyeMO at Shinshu University Hospital") has advanced to the next phase of testing for eyeMO[*1], a portable, low-cost, home-based, remote and in-office ophthalmic OCT[*2] device for monitoring of retinal diseases. This phase of the study will explore the potential of the technology for effectively monitoring patients in their own homes.

The feasibility[*3] assessment phase of this clinical trial involved healthcare professionals evaluating the clinical utility of eyeMO scans for assessing the condition of the retina in both healthy individuals and patients with retinal diseases. Additionally, clinicians determined if the measurement values for retinal thickness could be utilized in subsequent steps of the investigation.

During the next phase, patients will use eyeMO at home and healthcare professionals will then assess the validity of the retinal condition measurements taken by the patients, themselves.

Ryo Kubota, MD, PhD, Chairman, President, and CEO of Kubota Vision Inc., stated, "I am pleased to announce that we have moved to the next step of verifying the use of this device in patients' homes. Through this trial, we expect that eyeMO, our remote ophthalmic retinal monitoring device, will enhance convenience for patients with diabetic macular edema and optimize treatment timing, ultimately maximizing the therapeutic effects of interventions."

In this clinical trial, rental income is anticipated; however, due to the current difficulty in making objective calculations, disclosure of the consolidated earnings forecast for the fiscal year ending December 2024 is being withheld. Although potential impacts on the earnings forecast may exist, quantifying these effects at this time is challenging. A prompt disclosure of any revised consolidated earnings forecast will be made as soon as the impact can be accurately calculated.

[*1] eyeMO is a product name for the Patient Based Ophthalmology Suite (PBOS).

[*2] Optical Coherence Tomography (OCT) is a non-invasive tool that uses light waves to take cross-section pictures of the retina.

[*3] "Feasibility" refers to the process or study of evaluating the viability of clinical research. Specifically, it involves assessing whether the clinical study can proceed as planned by examining various conditions necessary for conducting the research, such as patient recruitment and data collection.

About eyeMO

eyeMO is a low-cost, home-based, ophthalmic self-monitoring OCT device. This small handheld device addresses needs in mobile Health (mHealth[*4]) applications for self-monitoring of retina health by patients in the home and in remote field locations. eyeMO aims to improve ophthalmic treatment outcomes in patients diagnosed with and treated for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other neovascular retinal diseases. eyeMO is being designed to detect nascent disease progression and support patient re-treatment prior to irreversible vision loss due to disease progression. Key features are low cost and a patient-friendly design to be used directly by patients at home. eyeMO is being designed to capture changes in retinal anatomy. Network

connectivity and cloud-based technologies are used to alert the patients and their physicians of disease progression and re-treatment needs.

[*4] mHealth refers to the usage of mobile communications technology and devices to enhance access to healthcare information, improve distribution of routine and emergency health services, and provide diagnostic services.

About Kubota Vision Inc.

Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group's pipeline includes a wearable device for myopia control using Kubota Glass technology and a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients. https://www.kubotavision.com/; https://www.kubotaholdings.co.jp/en/

Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision's parent company) investor relations website (https://www.kubotaholdings.co.jp/en/ir/) and on the SEC's website (http://www.sec.gov).

Media and Investor Relations Contact:

Press and Media Inquiries
Phone: +81-3-6550-8928
Email: pr@kubotaholdings.co.jp